Summary:
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
Criteria:- Willing and able to provide written informed consent.
- Male or female patients 18 to 65 years of age (inclusive).
- Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorder (DSM-5) for at least 1 year.
- Symptomatically stable within the past two months.
Qualified Participants May Receive:
Monetary compensation for participating.